As stated in Invent Medic’s recently published interim report, the company is a registered as a provider for two Swedish health care regions. The registration enables these regions to order Efemia before finalising public procurements.

In addition to being registered as a provider, Invent Medic has submitted offers in two ongoing public procurement processes in Sweden. The company expects that potential contracts as a result of these procurements will come into effect in H1 2020.

“This order is a result of our extensive efforts to present Efemia to important health care professionals such as pelvic floor therapists, physiotherapists and gynaecologists. They see a concrete demand for an effective and non-surgical SUI solution, and some of them contacted their region to order Efemia. This development is expected, but at the same time very positive as the public health care system reaches many women with SUI in an effective manner,” says Invent Medic´s CEO Karin Bryder.

In addition to Sweden, Efemia is available in Denmark, and launches are ongoing in Q4 2019 in Germany and the UK. The product will also be launched in the Netherlands and Belgium in Q1 2020. As Efemia becomes available in an increasing number of markets, the company expects that more and larger public procurements will be initiated where Invent Medic and its regional distributor can participate with Efemia.

For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
E-mail: info@inventmedic.com

Invent Medic Sweden AB, Company registration number 556682-1046, has developed a medical device for non-surgical relief of female stress urinary incontinence. The inventors behind the product, Jan Clarén and Lars-Olof Henriksson, have been involved in the development and performance of the surgical method TVT, which is now known as the Golden Standard for surgical treatment of female stress incontinence. The product is based on the same scientific basis and has similar mechanism of action as the surgical method but is based on a non-surgical support and is designed so that the woman can use the product when needed. This product has the potential to satisfy a major medical need and could thus have a significant market value. Invent medic"s vision is to offer new and innovative medical devices and treatment methods to women with the goal of improving their health and quality of life. The offer shall include safe, effective and safe products and treatment methods that should be easy to use and which will provide health economic benefits to society. Invent Medic Sweden AB is listed on Aktietorget. Ticker is IMS and the share"s ISIN code is SE0007603402. For more information see www.inventmedic.com and www.spotlightstockmarket.com.